Delta Ratio for Mixed Acid-Base Disorders
The delta ratio (delta anion gap / delta bicarbonate) identifies mixed acid-base disorders in the presence of a high anion gap metabolic acidosis. It reveals whether a concurrent metabolic alkalosis or normal anion gap acidosis is also present.
Score interpretation
Delta ratio < 0.4: Bicarbonate has fallen more than the anion gap has risen. Concurrent normal anion gap (hyperchloraemic) acidosis also present.
→ Identify both HAGMA and NAGMA causes. Consider: diarrhoea, RTA, saline infusion alongside DKA, lactic acidosis, uraemia.
Delta ratio 0.4–0.8: Suggests mixed high-AG and normal-AG metabolic acidosis.
→ Investigate for combined causes. Typical in early DKA + concurrent diarrhoea or RTA.
Delta ratio 0.8–2.0: Pure high anion gap metabolic acidosis. No major concurrent metabolic disorder.
→ Investigate cause of HAGMA: DKA, lactic acidosis, uraemia, toxic alcohols, salicylates.
Delta ratio > 2.0: Anion gap has risen more than bicarbonate has fallen — a concurrent metabolic alkalosis is present.
→ Identify metabolic alkalosis cause: vomiting, NG suction, loop diuretics, hypokalaemia, exogenous bicarbonate. Common in DKA with persistent vomiting.
Interpretation bands for the Delta Ratio. Apply clinical judgement and local guidance.
References
- Mehta AN, et al. Mixed acid-base disturbances: an approach to diagnosis and management. Postgrad Med. 2008;120(3):54–62.
Related
Curated clinical cross-links plus same-class fallbacks.
- Sodium Bicarbonate · Alkali Therapy (Metabolic Acidosis / CKD-Related Acidosis)
- Noradrenaline (Norepinephrine) · Vasopressor (Alpha-1 and Beta-1 Agonist)
- Tranexamic Acid (ICU/Trauma/Surgical) · Antifibrinolytic
- Ephedrine hydrochloride · Mixed alpha/beta-adrenergic agonist (vasopressor)
- Trimetazidine · Metabolic Anti-Anginal
- Acipimox · Lipid-modifying agent (Nicotinic acid derivative)
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.